ACAAI

Wellness Pioneer Russell Jaffe, MD, PhD, CCN and Bone Health Expert Susan Brown, PhD, CNS, Launch Book, "Natural Bone Health: A Practitioner's Guide to Healthy Bone, Joints and Muscles."

Retrieved on: 
Friday, September 16, 2022
ACT, CCN, Osteoporosis, Practitioner, Medicare, Policy, New, Center, Alternative, Bone density, Patient, Technology, Amazon (company), Research, Time, Diet, Prevalence, ASIP, ACAAI, Book, Disease, MBA, Doctor of Philosophy, Square One, Man, Mortality, ACN, MPA, FRSM, Bone, Autoimmunity, MD, Regeneration, Diabetes, Menopause, Joint, Certification, Dell, Publication, Thought, Jayashree, TCM, Program, CNS, Multimedia, Education, Muscle, Dietary supplement, Medical imaging, Calcium

ASHBURN, Va., Sept. 16, 2022 /PRNewswire/ -- Osteoporosis is a complex and multifactorial disorder that is growing in prevalence. More than half of Medicare-aged women and more than a fifth of comparable age men have one or more osteoporotic fractures confirmed during their lifetime. Recovery from large bone fractures is slow and leads to a more sedentary and less engaged life with greater morbidity and accelerated mortality.

Key Points: 
  • "Natural Bone Health: A Practitioner's Guide to Healthy Bone, Joints and Muscles" is now available for purchase.
  • Those who diligently work through the steps of our program put control back into their control systems, gain bone strength, and reduce fracture risk."
  • Natural Bone Health: A Practitioner's Guide to Healthy Bone, Joints and Muscles is now available for purchase on Amazon.com and at https://www.perqueintegrativehealth.com/natural-bone-health-a-practition...
    Russell Jaffe, MD, Ph.D., CCN, is an internist and immunologist.
  • Dr. Jaffe helped advance several adjunctive healthcare approaches including medical acupuncture (TCM), certified clinical nutrition (CCN), health coaching, and predictive biomarkers.

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Retrieved on: 
Friday, September 16, 2022
Adult, Observation, Therapy, Investor, Injection, Trial of the century, Safety, American College, Risk, University of Auckland, CRISPR, Nobel Prize, Medicine, Intellia Therapeutics, Faculty, Form 10-K, Private Securities Litigation Reform Act, ACAAI, Hereditary angioedema, Bradykinin, U.S. Securities and Exchange Commission, Patient, Clinical trial, History, Cancer, Cas9, Cell, Prekallikrein, Genetic disorder, Liver, Tissue, Degenerative disease, SC, NASDAQ, Plasma kallikrein, KLKB1, Security (finance), Pharmacokinetics, GLOBE, SEC, HAE, University of Auckland Faculty of Medical and Health Sciences, Annual report, Genome, Webcast, University, Plasma, NTLA, Aluminium, Pharmaceutical industry, Vaccine

The interim data were shared today in an oral presentation at the 2022 Bradykinin Symposium held in Berlin, Germany.

Key Points: 
  • The interim data were shared today in an oral presentation at the 2022 Bradykinin Symposium held in Berlin, Germany.
  • To date, all three patients in the 25 mg dose cohort have reached the end of this initial observation period.
  • Treatment with a single dose of 25 mg of NTLA-2002 resulted in a mean reduction in HAE attacks of 91% throughout the 16-week observation period.
  • This press release contains forward-looking statements of Intellia Therapeutics, Inc. (Intellia or the Company) within the meaning of the Private Securities Litigation Reform Act of 1995.

Ready, Set, Food! Advances Childhood Food Allergy Education Efforts Through Relationship with Providence

Retrieved on: 
Tuesday, June 14, 2022
Science, AAAAI, Entrepreneurship, Caregiver, Allergen, Nutrition, Anxiety, LinkedIn, Child, CME, American Academy, Partnership, American Academy of Allergy, Asthma, and Immunology, American College, Allergist, Pediatrics, Organization, Asthma, Multimedia, Allergy, Physician, Hospital, Risk, Health, American College of Allergy, Asthma and Immunology, Parent, Food allergy, Twitter, ACAAI, Catholic (term), Instagram, View, Medical device, Medicine, Facebook, Ready, Food

LOS ANGELES, June 14, 2022 /PRNewswire/ -- Ready, Set, Food!, an early allergen introduction leader that specializes in baby food and educational resources to help families introduce food allergens safely and easily to babies, is expanding its efforts to inform and educate parents on the topic of food allergen introduction through a relationship with Providence, a top provider of pediatric and primary care.

Key Points: 
  • However, national surveys show that only ~30% of pediatricians teach parents about food allergy prevention.
  • Using educational content developed by nationally recognized food allergy experts, Ready, Set, Food!
  • Providence is also taking advantage of other resources the relationship offers, like in-clinic educational materials for families (brochures) and providers (CME webinars from allergy experts and summaries of food allergy prevention medical guidelines).
  • Using educational content developed by nationally recognized food allergy experts, Ready, Set, Food!

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results

Retrieved on: 
Thursday, December 9, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, U.S. Securities and Exchange Commission, Fiscal year, Phase II, NDA, Forward-looking statement, Research, Patient, HAE, Net, American College of Allergy, Asthma and Immunology, D, Security (finance), ACAAI, DME, KALV, Safety, Annual report, Private Securities Litigation Reform Act, Diabetic retinopathy, American College, Form 10-K, Hereditary angioedema, COVID-19, FDA, NASDAQ, Risk, Poster, Investment, Calendar, Pharmaceutical industry, the KOMPLETE Clinical Trial, KalVista Pharmaceuticals, Inc., THE KOMPLETE CLINICAL TRIAL, KALVISTA PHARMACEUTICALS, INC.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2021.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2021.
  • Second Fiscal Quarter and Recent Business Highlights:
    Initiated KOMPLETE, the Phase 2 clinical trial of KVD824 that is currently enrolling patients.
  • Second Fiscal Quarter Financial Results:
    Revenue: No revenue was recognized for the three months ended October 31, 2021 or October 31, 2020.
  • KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.

USA Equities Corp. Introduces AllergiQT™ – Quick Test, Further Expanding Market Presence

Patient, Private Securities Litigation Reform Act, Immunotherapy, Algorithm, Security (finance), COPD, Biophysical environment, Anxiety, Allergy, Income, Allergist, Technology, Forward-looking statement, Medicare, Company, Asthma, Coronary artery disease, Hypertension, Prevalence, Needle, ACAAI, Budget, Solution, U.S. Securities and Exchange Commission, Conditional sentence, Vital signs, Physician, GLOBE, Clinician Administered PTSD Scale, OTCQB, American College of Allergy, Asthma and Immunology, Digital, Â, FDA, Physical examination, Cosmetics, Health insurance, Pharmaceutical industry, Medical imaging

Troy Grogan, Chief Executive Officer of USA Equities Corp. commented, Were very excited to announce our latest new product introduction, AllergiQT, which further expands our portfolio of income generating products in the very attractive allergy test end market.

Key Points: 
  • Troy Grogan, Chief Executive Officer of USA Equities Corp. commented, Were very excited to announce our latest new product introduction, AllergiQT, which further expands our portfolio of income generating products in the very attractive allergy test end market.
  • As a result, USA Equities is able to offer the market a comprehensive solution including screening, testing and immunotherapy treatment.
  • This segment comprises a significant portion of our total addressable market of approximately 250,000 independent, primary care physicians.
  • USA Equities Corp. (OTCQB: USAQ) is a medical device company providing digital medicine solutions and point-of-care-diagnostic tests to primary care physicians.

Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates

Retrieved on: 
Wednesday, November 10, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Society, GVHD, Urine, Safety, Corporation, American Society of Nephrology, Australian Taxation Office, Private Securities Litigation Reform Act, SLE, Type, Tax, R, Itolizumab, Investment, Trial of the century, Lupus nephritis, Asthma, COVID-19, ACR, Risk, Partnership, American College of Rheumatology, SEC, EQUIP, Proteinuria, American College of Allergy, Asthma and Immunology, ASN, ACAAI, Nasdaq, Patient, Feedback, American College, Pharmaceutical industry

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the third quarter 2021, and provided an update on its clinical programs.

Key Points: 
  • Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the third quarter 2021, and provided an update on its clinical programs.
  • General and administrative (G&A) expenses for the third quarter of 2021 were $2.9 million, compared with $2.3 million for the same period in 2020.
  • Cash used in operations for the third quarter of 2021 was $7.0 million compared to $7.0 million in the second quarter of 2021.
  • Cash, cash equivalents and short-term investments totaled $90.7 million as of September 30, 2021, compared to $97.6 million as of June 30, 2021.

Astria Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

Retrieved on: 
Wednesday, November 10, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Therapy, Plasma, Abdomen, Catabasis Pharmaceuticals, IND, Degenerative disease, NASDAQ, Disease, Swelling, Quelli che... il Calcio, Hereditary angioedema, D, Asthma, COVID-19, Instagram, Face, Facebook, Forward-looking statement, Neonatal Fc receptor, Annual report, Bradykinin, File, Twitter, Acquisition, Plasma kallikrein, YTE, Company, Research, NORD, Nasdaq, Half-life, LinkedIn, Lanadelumab, SEC, Hope, Pharmacy, Drug discovery, American College of Allergy, Asthma and Immunology, Investigational New Drug, Review, National Organ Transplant Act of 1984, ACAAI, Genetic disorder, Time, Patient, Risk, FDA, American College, Allergy, Fine chemical, Pharmaceutical industry, Lithium, Animal, Reinsurance, Air cargo

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
  • Our new company name, Astria, embodies our commitment to put patients first in all that we do.
  • On September 8, 2021, the Company formally changed its name from Catabasis Pharmaceuticals to Astria Therapeutics.
  • Cash Position: As of September 30, 2021, Astria had cash and cash equivalents of $131.8 million, compared to $139.5 million as of June 30, 2021.

KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE

Retrieved on: 
Monday, November 8, 2021
Health, Clinical Trials, General Health, Pharmaceutical, Cardiology, Biotechnology, University, HAE, Plasma, NASDAQ, American College of Allergy, Asthma and Immunology, Hereditary angioedema, University of Cincinnati, University of Cincinnati Academic Health Center, KALV, FACP, ACAAI, Poster, Patient, American College, Pharmaceutical industry

Data presentations included an oral presentation and poster presentation on Phase 2 data for KVD900, KalVistas lead program for oral on-demand treatment of hereditary angioedema (HAE) attacks.

Key Points: 
  • Data presentations included an oral presentation and poster presentation on Phase 2 data for KVD900, KalVistas lead program for oral on-demand treatment of hereditary angioedema (HAE) attacks.
  • Treatment of HAE attacks with KVD900 achieved rapid plasma exposure which was associated with faster improvements in initial symptom relief compared with placebo.
  • As the first oral on-demand treatment to demonstrate this early therapeutic effect for patients, KVD900 may represent a remarkable advancement for management of the disease.
  • KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints.

BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)

Retrieved on: 
Friday, November 5, 2021
Quality of life, Safety, BioCryst Pharmaceuticals, University, HAE, Cincinnati, Medicine, Hereditary angioedema, Patient satisfaction, GLOBE, RESEARCH, University of California, San Diego Performance-Based Skills Assessment, Lanadelumab, ACAAI, Nasdaq, Patient, Internal medicine, PARK, American College, Pharmaceutical industry

These data show that, regardless of which therapy patients switched from, or when they switched, ORLADEYO provided consistently low attack rates when used as a monotherapy.

Key Points: 
  • These data show that, regardless of which therapy patients switched from, or when they switched, ORLADEYO provided consistently low attack rates when used as a monotherapy.
  • These important findings add to real-world evidence that this oral, once-daily therapy is a beneficial treatment option for many HAE patients.
  • Following initiation of ORLADEYO, patients experienced low HAE attack rates that were sustained throughout the treatment period (median attack rate of 0.0 attacks per month through month 12), consistent with previously reported data.
  • Sustained reductions in mean and median HAE attack rates were observed after patients switched to ORLADEYO.

DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021

Retrieved on: 
Monday, November 1, 2021
Safety, Food, Research, Life, 2021 Essex County Council election, Immunotherapy, Vaccine, Knowledge, ACAAI, ISIN, AMF, DBV Technologies, Patient, U.S. Securities and Exchange Commission, SEC, Risk, Nasdaq, Allergy, Trial of the century, COVID-19, Skin, Press release, DBV, American College, Immune system, Hope, Allergen, Sale, Ticker, Pharmaceutical industry, Medical device

DBV will also host a booth in the ACAAI exhibit hall.

Key Points: 
  • DBV will also host a booth in the ACAAI exhibit hall.
  • These data presented at ACAAI contribute to our understanding of and excitement for the potential real-world use of Viaskin Peanut, if approved.
  • DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ.
  • Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.